1. Economic evaluation of a trial exploring the effects of a web-based support tool for parents of children with juvenile idiopathic arthritis.
- Author
-
Flood, Chris, Hirani, Shashivadan P, Mulligan, Kathleen, Taylor, Jo, Harris, Sally, Wedderburn, Lucy R, and Newman, Stanton P
- Subjects
- *
INTERNET & economics , *MEDICAL economics , *SELF-evaluation , *MEDICAL care use , *COST control , *JUVENILE idiopathic arthritis , *COST effectiveness , *RESEARCH funding , *RANDOMIZED controlled trials , *CHILDREN'S hospitals , *PARENTING , *DESCRIPTIVE statistics , *TELEMEDICINE , *RESEARCH , *PSYCHOLOGICAL stress , *SOCIAL support , *COMPARATIVE studies , *COGNITIVE therapy , *CONFIDENCE intervals , *MEDICAL care costs , *ECONOMICS - Abstract
Objective To explore the cost-effectiveness of a web-based support tool for parents of children with Juvenile idiopathic arthritis. Methods A multi-centred randomized controlled trial was conducted in paediatric rheumatology centres in England. The WebParC intervention consisted of online information about JIA and its treatment and a toolkit using cognitive-behavioural therapy principles to support parents manage their child's JIA. An economic evaluation was performed alongside the trial involving 220 parents. The primary outcome was the self-report Pediatric Inventory for Parents measure of illness-related parenting stress, with two dimensions: difficulty and frequency. These measures along with costs were assessed post intervention at 4 and 12 months. Costs were calculated for healthcare usage using a UK NHS economic perspective. Data was collected and analysed on the impact of caring costs on families. Uncertainty around cost-effectiveness was explored using bootstrapping and cost-effectiveness acceptability curves. Results The intervention arm showed improved average Pediatric Inventory for Parents scores for the dimensions of frequency and difficulty, of 1.5 and 3.6 respectively at 4 months and 0.35 and 0.39 at 12 months, representing improved PIP scores for the intervention arm. At both 4 and 12 month follow-up, the average total cost per case was higher in the control group when compared with the intervention arm with mean differences of £360 (95% CI £29.6 to £691) at 4 months and £203 (95% CI £16 to £390) at 12 months. The probability of the intervention being cost-effective ranged between 49% and 54%. Conclusion The WebParC intervention led to reductions in primary and secondary healthcare resource use and costs at 4 and 12 months. The intervention demonstrated particular savings for rheumatology services at both follow-ups. Future economies of scale could be realised by health providers with increased opportunities for cost-effectiveness over time. Trial registration ISRCTN, ISRCTN13159730. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF